LRRK2 and proximal spinal muscular atrophy: Indeed, the use of specific PKC antisense oligonucleotides to reduce PKC is an attractive potential treatment of neurodegenerative diseases since antisense strategies are already successfully used to ameliorate clinical manifestation of spinal muscular atrophy [109], to decrease superoxide dismutase 1 in order to treat amyotrophic lateral sclerosis [110], and to reduce leucine-rich repeat kinase 2 (LRRK2) protein levels in Parkinson’s disease treatment [111], among others [112,113].